Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
17 May 24
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
13 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
8-K
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
2 Apr 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
25 Mar 24
S-8
Registration of securities for employees
27 Feb 24
8-K
Other Events
9 Feb 24
424B5
Prospectus supplement for primary offering
9 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Entry into a Material Definitive Agreement
27 Nov 23
EFFECT
Notice of effectiveness
22 Nov 23
8-K
Departure of Directors or Certain Officers
21 Nov 23
CORRESP
Correspondence with SEC
17 Nov 23
UPLOAD
Letter from SEC
16 Nov 23
S-3
Shelf registration
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
13 Nov 23
8-K
Entry into a Material Definitive Agreement
4 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
10 Aug 23
8-K
Entry into a Material Definitive Agreement
26 Jun 23
8-K
Termination of a Material Definitive Agreement
14 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Departure of Directors or Certain Officers
27 Apr 23
8-K
Departure of Directors or Certain Officers
14 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
8-K
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
30 Mar 23
10-K
2022 FY
Annual report
30 Mar 23
S-8
Registration of securities for employees
27 Feb 23
8-K
Amendments to Articles of Incorporation or Bylaws
24 Feb 23
Latest ownership filings
4
Venkatesh Srinivasan
3 May 24
4
Venkatesh Srinivasan
12 Apr 24
SC 13G
Point72 Asset Management, L.P.
5 Apr 24
4/A
WILLIAM J NEWELL
22 Mar 24
4/A
LINDA A FITZPATRICK
22 Mar 24
4/A
EDWARD C ALBINI
22 Mar 24
4
LINDA A FITZPATRICK
7 Mar 24
4
Venkatesh Srinivasan
7 Mar 24
4
WILLIAM J NEWELL
7 Mar 24
4
Hans-Peter Gerber
7 Mar 24
4
Jane Chung
7 Mar 24
4
Anne Elizabeth Borgman
7 Mar 24
4
EDWARD C ALBINI
7 Mar 24
4
WILLIAM J NEWELL
6 Mar 24
4
LINDA A FITZPATRICK
6 Mar 24
4
Jane Chung
6 Mar 24
4
EDWARD C ALBINI
6 Mar 24
4
Venkatesh Srinivasan
5 Mar 24
4
WILLIAM J NEWELL
5 Mar 24
4
LINDA A FITZPATRICK
5 Mar 24
4
Jane Chung
5 Mar 24
4
EDWARD C ALBINI
5 Mar 24
4
Anne Elizabeth Borgman
4 Mar 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
Rubric Capital Management LP
12 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
WILLIAM J NEWELL
31 Jan 24
4
EDWARD C ALBINI
31 Jan 24
4
LINDA A FITZPATRICK
31 Jan 24
4
Nicki Vasquez
31 Jan 24
144
Notice of proposed sale of securities
29 Jan 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
17 Jan 24
4
Jane Chung
4 Dec 23
SC 13G
ADAGE CAPITAL PARTNERS GP, L.L.C.
10 Oct 23
4
Hans-Peter Gerber
19 Sep 23
3
Hans-Peter Gerber
19 Sep 23
4
Brunilda Shtylla
29 Aug 23
4
Brunilda Shtylla
28 Aug 23
144
Notice of proposed sale of securities
25 Aug 23